This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           May 06, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

The great success and enduring dilemma of cervical cancer screening
NPR
Cervical cancer, which still kills about 4,000 American women every year, is almost entirely preventable. Proper screening can catch early warning signs that could lead to cancer without the right treatment. But how often women should get screened and which tests should be used has been hotly debated by women, doctors and medical researchers for the past decade. Recently, the American College of Physicians weighed in with guidelines, endorsed by the American College of Obstetricians and Gynecologists, that aim to reduce unnecessary screening.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


SGO palliative care statement in May 2015 Gynecologic Oncology
The May 2015 issue of Gynecologic Oncology features the SGO Statement, “Comprehensive care in gynecologic oncology: The importance of palliative care.” According to the statement: “A collaborative team approach is most effective in addressing the physical, psychosocial, and existential needs of patients, with support beginning for patients at time of initial diagnosis transitioning through effective management of treatment associated-toxicity, and ultimately for some moving to hospice at the end of life.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Investigational personalized cellular therapy tolerated well by patients (Phase 1 trial)
Oncology Nurse Advisor
Genetically modified versions of patients' own immune cells successfully traveled to tumors they were designed to attack in an early stage trial for mesothelioma and pancreatic and ovarian cancers. The interim results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania. The data adds to a growing body of research showing the promise of chimeric antigen receptor (CAR) T cell technology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


SURGERY


Raplixa approved to help control surgical bleeding
HealthDay News via The Clinical Advisor
The FDA has approved a spray-dried fibrin sealant (Raplixa) to help control bleeding during surgery, the agency said in a news release. Raplixa's use is sanctioned when standard surgical techniques — such as suture, ligature, or cautery — are "ineffective or impractical," the FDA said. The spray-dried fibrin sealant is dissolved in the blood and triggers a reaction that promotes clotting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Factors affecting women's election to undergo bilateral mastectomy identified
Oncology Nurse Advisor
Physicians and cancer survivors are the primary and secondary sources of information, respectively, influencing women to undergo a bilateral mastectomy as their treatment for breast cancer when there is only known cancer in one breast, according to a study presented at the ONS 40th Annual Congress. In this retrospective study, researchers, including oncology nurse navigators and a nurse scientist, surveyed 156 women who elected to have a contralateral prophylactic mastectomy (CPM).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Register today!

Join ECG in Chicago on May 29th for an interactive symposium on BRCA Related Ovarian Cancer, Chaired by Thomas J. Herzog, MD.

Register today

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.


MORCELLATION


Two congressmen turn up heat on power morcellators
Medscape (Free login required)
Amy Reed, MD, PhD, and her husband, Hooman Noorchashm, MD, PhD, have waged an often lonely campaign to end the use of cancer-dispersing power morcellators in gynecologic procedures and subject all medical devices to tougher safety standards. Lately, however, the couple has gained some influential supporters in the form of two congressmen from their home state of Pennsylvania as well as America's Health Insurance Plans (AHIP), a trade association. The physicians hope that these allies will nudge Congress to hold hearings on medical-device safety.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


RESEARCH


Changes in the blood can predict cancer years in advance
CBS News
A simple blood test may be able to predict cancer years before a diagnosis. According to new research from Northwestern Medicine in collaboration with Harvard University, scientists detected a distinct pattern in the changing lengths of telomeres, the protective end caps on our strands of DNA, which may act as a biomarker to predict cancer years before it develops. The study, which is the first to track telomere changes over years in people developing cancer, was published in EBioMedicine.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


A protein 'brake' in metabolic reprogramming that restrains senescent cells from becoming cancerous
Health Canal
In recent years, research has shown that cancerous cells have a different metabolism – essential chemical and nutritional changes needed for supporting the unlimited growth observed in cancer– than normal cells. Now, scientists at The Wistar Institute have identified a way that cells can reprogram their metabolism to overcome a tumor-suppressing mechanism known as senescence, solidifying the notion that altered metabolism is a hallmark of cancer progression. The findings were published online by the journal Cell Reports.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

April 29, 2015
April 22, 2015
April 15, 2015
April 8, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063